Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Advances in targeted therapies for ALL

Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses the newest and most promising targeted ALL therapies. Prof. Marks discusses blinatumomab, which has shown impressive results in establishing MRD negativtiy, and CAR T-cells, which may offer the hope of long-term survival to patients who were previously considered to be incurable.